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placebo or D-ER nonresponders, respectively, at weeks 6 (ES0.55, p0.01; ES0.76,
p0.01), 10 (ES0.48, p0.04; ES0.55, p0.01), and 14 (ES0.77, p0.01; ES0.67,
p0.01). No improvement was seen after D-ER discontinuation at weeks 16 and 18
(p0.05 for both). D-ER nonresponders did not show improvement vs. placebo at
any visit using either equation. CONCLUSIONS: Regardless of the mapping equa-
tion used, D-ER response was associated with an improvement in utility. The UK-
derived equation resulted in larger estimates of improvement than the NA-derived
equation.
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OBJECTIVES: Although information is available on how adults with epilepsy value
their quality-of-life (QoL), there are no published data regarding the short-term
impact of seizures on children or adults. Furthermore, utility studies in epilepsy
have concentrated on examining the impact of different seizure frequencies on
patients’ QoL rather than the impact of seizures themselves. Given that adminis-
tration of questionnaires during (or shortly after) a seizure is impossible and un-
ethical, alternative methods are required. As part of the BUCCOLAM® (oromusocal
midazolam) submission to the AWMSG, an exploratory analysis was conducted to
determine the short-term impact of seizures on QoL.METHODS: Four UK clinicians
were asked to qualitatively describe the impact of seizure on children and parents/
carers, to estimate utility values during and shortly after a seizure using the EQ-
5D-5L questionnaire, and to assess how long it takes children to recover from
seizures of different severities. RESULTS: Clinicians described the utility of pa-
tients during seizure as equivalent to death (not capable of experiencing or doing
anything), and the parents’/carers’ quality of life being significantly reduced (low-
est level on anxiety/depression scale). Using the EQ-5D-5L, the baseline utility of a
normal healthy child with epilepsy was estimated at 0.92. This decreased to -0.334
during seizure, 0.722 immediately following seizure (for a short seizure with no
ambulance required) and 0.1 for a more severe seizure (where an ambulance was
required). The mean prolonged acute seizure duration in children was estimated at
5–20 minutes, with time to full recovery estimated as 24 hours for a seizure not
leading to hospital admission, and 3-5 days for a seizure requiring hospitalisation.
CONCLUSIONS: Seizures appear to have a major impact on the QoL of both children
and their parents/carers. Although short-term in nature, seizures are also associ-
ated with disproportionate recovery times, with a resulting impact on QoL.
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OBJECTIVES:The Huntington Clinical Self-Reported Instrument (H-CSRI) is the first
subjective clinimetric scale for patients with Huntington’s disease (HD). Such an
instrument offers the advantage of allowing a remote follow-up, and collection of
information on the development of motor, functional and behavioural symptoms
of HD, perceived by the patients themselves. The objective of this study was to
adapt and cross-culturally validate the H-CSRI for Spain. METHODS: The original
questionnaire included three subscales assessing patients’ motor ability (13 Likert-
type items in four dimensions), functional capacity (seven Yes/No questions) and
behavioural ability (13 Likert-type items in four dimensions). The instrument was
translated forwards and backwards by native speakers. The hospital ‘Hospital Ramon
y Cajal’ provided their patients with the questionnaire. Classical test theory and
item response theory were used to assess its clinimetric properties. Cross-cultural
validation was assessed by differential item functioning analysis (DIF). RESULTS:A
total of 59 patients filled in the H-CSRI questionnaire. The H-CSRI showed satisfac-
tory psychometric proprieties. Item response rates ranged from 84% to 94%. A floor
effect was found for five items in the behavioural dimension. The H-CSRI showed
an acceptable reliability, as Cronbach’s alpha coefficients were higher than 0.85.
Factor analyses demonstrated that the data were structured in the same way as for
the French and the Italian versions. Item internal consistency (IIC) and item dis-
criminant validity criteria were met for most items (i.e. IIC was  0.40, and corre-
lations between items and their respective rest-scores in one dimension were all
greater than correlations with another dimension). The DIF analyses showed no
item bias versus the Italian or French versions. CONCLUSIONS: The Spanish ver-
sion of the H-CSRI showed acceptable clinimetric properties. This study supports
the usefulness of the H-CSRI questionnaire to assess the clinical status of patients,
although it is limited by the small sample size.
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OBJECTIVES: To assess the frequency, severity, use of hypnotics and impact of
sleep problems in the community in the UK. METHODS: Questionnaires were in-
serted in a national newspaper and patients with sleep problems requested to
complete them and return by post. RESULTS: Two thousand and eighty-two ques-
tionnaires were returned. Within the questionnaires returned not all of the ques-
tions were answered with some questions being more frequently completed than
others. We report the outcome for individually completed questions. Sixty-four
percent of respondents were female, 92% aged forty or over and 57% over 60; 94% of
patients reported insomnia for more than a year. Seventy-seven percent described
sleep as bad or very bad. 64% complained of feeling tired after rising and starting
the next day. Only 3% thought they got off to sleep in less than 20 minutes with 55%
reporting taking greater than 1 hour to get to sleep. A total of 86% visited the doctor
less than 4 times per year but apparently did not complain of insomnia; 44% re-
ported having received hypnotics from the doctor in the past but only 2% currently
taking them. Seven percent of patients attributed their sleep problems to pain; 42%
of patients get up regularly to use the bathroom but in general did not attribute
their sleep problems to this reason. In contrast 40% of respondents felt that their
problems were purely age-related. CONCLUSIONS: Insomnia is a common, long-
standing, serious problem which afflicts and impacts upon older rather than
younger people. While most respondents had received hypnotics in the past they
were not currently taking them despite continuing to suffer from insomnia. There
appears a common acceptance that sleep problems are simply a function of ageing.
This study demonstrates the need for patient education and for physicians to
address the problem of insomnia in older age.
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OBJECTIVES: Spasticity and fatigue are common in patients with Multiple Sclerosis
(MS) and can highly affect patients’ quality-of-life (QoL). A burden-of-disease study
was performed to gain real-life data on MS-related fatigue and the patients’ and
physicians’ evaluation of fatigue and QoL. METHODS: The MOVE 1 (MObility Im-
proVEment) study included a cross-sectional investigation of fatigue and QoL of MS
spasticity patients, using the “Würzburger Erschöpfungsinventar bei Multipler
Sklerose” (WEIMuS, German MS-related fatigue questionnaire) and the EQ-5D QoL
instrument. WEIMuS total score (0-68; cut-off 32), cognitive (0–36; cut-off 17)
and physical (0–32; cut-off 16) fatigue subscores are obtained. EQ-5D includes 5
domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depres-
sion) with 3 answer levels (no, some and extreme problems). RESULTS: In total, 419
MS patients with spasticity were enrolled at 42 German centres from 4/2011 to
9/2011. 414 patients fulfilled selection criteria and were analyzed. Mean age was
48.6 ( 9.6) y., 64.3% were female. According to physicians, 27.3% of patients had
mild, 44.0% moderate and 28.7% severe spasticity. Fatigue was recorded by physi-
cians in 49.4% and by patients in 50.0% of cases as one of the most disturbing
spasticity associated symptoms. According to WEIMuS, total fatigue cut-off score
was reached by 48.0%, 53.8% and 54.5% of patients with mild, moderate or severe
spasticity; while physical fatigue was observed in 52.9%, 69.6% and 66.3% and cog-
nitive fatigue in 37.3%, 35.7% and 37.6% of these subgroups, respectively. With
increasing spasticity severity the mean EQ-5D index value decreased (0.60.2 to
0.30.3) and the number of patients with “extreme problems” raised, particularly
in the domains “mobility” (0% to 13.6%), “self-care” (1.0% to 20.0%) and “usual
activity” (2.9% to 25.5%). CONCLUSIONS: The occurrence of fatigue in MS patients
increases with spasticity severity, impairing patients’ QoL in parallel. Patients’ and
physicians’ evaluations are aligned.
PND55
MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29): ITS VALIDITY AND
RESPONSIVENESS IN CLINICAL TRIAL-BASED SUBJECTS
Guo S1, Proskorovsky I2, Phillips GA3
1United BioSource Corporation, Lexington, MA, USA, 2United BioSource Corporation, Dorval, QC,
Canada, 3Biogen Idec Inc., Weston, MA, USA
OBJECTIVES: The psychometric properties of the Multiple Sclerosis Impact Scale
(MSIS-29) have been well examined in community-based samples using cross-
sectional data, but not yet in trial-based samples using longitudinal data. This
analysis examined MSIS-29’s validity and responsiveness using longitudinal data
from patients with relapsing-remitting multiple sclerosis (RRMS) enrolled in the
SELECT trial of daclizumab HYP. METHODS: The MSIS-29 and EQ-5D tariff and
visual analogue scale (VAS) were administered at baseline, 3, 6, and 12 months to
600 patients with RRMS who had mean age of 35.8 (SD8.91) years and Expanded
Disability Status Scale of 2.7 (SD1.17) at baseline. The convergent and discrimi-
nant validity of MSIS-29 was assessed by examining the strength of correlations
between the physical and psychological scores of the MSIS-29 and each of the five
EQ-5D dimensions at all time points. MSIS-29 responsiveness was evaluated by
examining the direction, magnitude, and pattern of change in MSIS-29 scores in
three patient subgroups defined by achieving an established minimal important
EQ-5D VAS change of 5.5 points at each time point from baseline (improved 5.5,
-5.5  stable 5.5, worsened -5.5). RESULTS: As expected, the MSIS-29 physical
scale was more highly correlated with the EQ-5D dimensions usual activities
(r0.66) and mobility (r0.62) and least correlated with anxiety/depression
(r0.48). Conversely, the psychological scale was more highly correlated with the
EQ-5D anxiety/depression (r0.64) and least correlated with personal care (r0.35)
and mobility (r0.42). The direction, magnitude, and pattern of change in the phys-
ical and psychological scores over time in each subgroup were consistent with
expectations, showing insignificant change among stable patients, but significant
change among those who improved or worsened. CONCLUSIONS: The MSIS-29 is a
valid and responsive measure among trial-based subjects. This analysis supports
its use as a disease-specific measure of treatment effect on the physical and psy-
chological well-being of MS patients.
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